ADMA Biologics Inc (ADMA)
6.81
+0.07
(+1.04%)
USD |
NASDAQ |
May 03, 16:00
6.80
-0.01
(-0.15%)
After-Hours: 20:00
ADMA Biologics Revenue (Quarterly): 73.90M for Dec. 31, 2023
Revenue (Quarterly) Chart
Historical Revenue (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | 73.90M |
| September 30, 2023 | 67.27M |
| June 30, 2023 | 60.12M |
| March 31, 2023 | 56.91M |
| December 31, 2022 | 49.98M |
| September 30, 2022 | 41.09M |
| June 30, 2022 | 33.90M |
| March 31, 2022 | 29.10M |
| December 31, 2021 | 26.38M |
| September 30, 2021 | 20.68M |
| June 30, 2021 | 17.83M |
| March 31, 2021 | 16.05M |
| December 31, 2020 | 13.96M |
| September 30, 2020 | 10.28M |
| June 30, 2020 | 7.788M |
| March 31, 2020 | 10.20M |
| December 31, 2019 | 12.04M |
| September 30, 2019 | 7.222M |
| June 30, 2019 | 6.561M |
| March 31, 2019 | 3.529M |
| December 31, 2018 | 4.056M |
| September 30, 2018 | 4.230M |
| June 30, 2018 | 4.657M |
| March 31, 2018 | 4.042M |
| Date | Value |
|---|---|
| December 31, 2017 | 12.00M |
| September 30, 2017 | 4.729M |
| June 30, 2017 | 3.399M |
| March 31, 2017 | 2.629M |
| December 31, 2016 | 3.328M |
| September 30, 2016 | 2.938M |
| June 30, 2016 | 2.272M |
| March 31, 2016 | 2.124M |
| December 31, 2015 | 2.512M |
| September 30, 2015 | 1.852M |
| June 30, 2015 | 1.310M |
| March 31, 2015 | 1.503M |
| December 31, 2014 | 1.489M |
| September 30, 2014 | 1.366M |
| June 30, 2014 | 1.500M |
| March 31, 2014 | 1.561M |
| December 31, 2013 | 0.424M |
| September 30, 2013 | 1.107M |
| June 30, 2013 | 0.7433M |
| March 31, 2013 | 0.7929M |
| December 31, 2012 | 0.5233M |
| September 30, 2012 | 0.3603M |
| June 30, 2012 | 0.2301M |
| March 31, 2012 | 0.0044M |
Revenues Definition
Revenues measure the total amount of value that a company brings in during a certain period. This is also considered the "top-line" of the income statement. Revenues are used for all operating expenses as well as other line items which eventually lead to the net income for the company. Revenue is an extremely important metric when analyzing a company. A company with efficient margins is able to turn revenues into the most net income.
Revenue (Quarterly) Range, Past 5 Years
6.561M
Minimum
Jun 2019
73.90M
Maximum
Dec 2023
29.54M
Average
20.68M
Median
Sep 2021
Revenue (Quarterly) Benchmarks
| Vanda Pharmaceuticals Inc | 45.27M |
| ANI Pharmaceuticals Inc | 131.65M |
| Ligand Pharmaceuticals Inc | 28.10M |
| Johnson & Johnson | 21.38B |
| Puma Biotechnology Inc | 72.18M |
Revenue (Quarterly) Related Metrics
| Net Income (Quarterly) | -17.64M |
| Total Expenses (Quarterly) | 59.67M |
| EPS Diluted (Quarterly) | -0.08 |
| Enterprise Value | 1.633B |
| Gross Profit Margin (Quarterly) | 42.06% |
| Profit Margin (Quarterly) | -23.88% |
| Earnings Yield | -1.91% |
| Operating Earnings Yield | 1.42% |
| Normalized Earnings Yield | -0.2082 |